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Nrf2 pathway has been known to be protective against cancer progression however recent studies have
revealed that the antioxidant activity of Nrf2 contributes to chemotherapy resistance. For many years,
hyperthermia has been used as an additional therapy to increase the efﬁciency of chemotherapy and
radiotherapy. Besides the positive effects of hyperthermia during treatment procedure, thermotolerance
has been found to develop against heat treatment. Although the involved molecular mechanisms have
not been fully clariﬁed, heat shock proteins (HSP) and proteasome activity are known to be involved in
the acquisition of thermotolerance. The aim of this study was to investigate the potential beneﬁcial
effects of combining hyperthermia with Nrf2 silencing to inhibit molecular mechanisms leading to in-
duction of defense mechanisms in transcription level. Following heat treatment of HT22 cells, HSP70 and
the proteasome levels and as well as proteasome activity were found to be elevated in the nucleus. Our
results demonstrated that Nrf2 silencing reduced defense mechanisms against heat treatment both in
antioxidant and proteolytic manner and Nrf2 may be a potential target for therapeutic approach in order
to improve the beneﬁcial effects of hyperthermia in cancer therapy.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hyperthermia (HT, thermal therapy, thermotherapy) which is
used to destroy cancerous cells or to prevent their further growth,
is a phenomenon that increases the body temperature with a
range from 40 to 48 °C [1,2]. Hyperthermia is considered to be an
effective cancer therapy approach particularly when combined
with chemotherapy and radiotherapy [3]. During hyperthermia
application, thermotolerance may develop against heat treatment
via various pathways [4,5]. Thermotolerance is referred as the
acquisition of a transient increased resistance to heat, which can
be induced by a short exposure to a nonlethal heat treatment.B.V. This is an open access article u
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B. Karademir).Therefore, it is important to inhibit the molecular mechanisms
that lead to thermotolerance in order to improve the antitumor
efﬁciency of hyperthermia. Although these molecular mechanisms
have not been fully clariﬁed, induction of proteostasis markers
such as heat shock proteins and proteasomal activity are known to
be involved in thermotolerance [6].
Heat shock proteins (HSPs) exist in high concentrations in the
cell and play a crucial role in sustaining protein homeostasis
during cellular stress such as heat, oxidative stress, inﬂammation
and irradiation [7]. They have four large and ubiquitous, ATP-de-
pendent families classiﬁed as HSP100, HSP90, HSP70, and HSP60
proteins in addition to small HSPs [8]. HSP expression is tightly
controlled in normal cells whereas it is enhanced by heat stress
and is often dysregulated in tumor cells [9,10]. Hyperthermia is a
protocol used to increase the efﬁciency of cancer therapy. The heat
shock response following heat treatment may lead to the devel-
opment of thermotolerance in tumor cells which reduces the
beneﬁcial effects of hyperthermia [6]. HSPs, especially HSP70 and
HSP90, have been linked to this mentioned therapy resistance [11–
13].
Proteasomal system is a crucial degradation pathway for the
oxidatively modiﬁed proteins that makes it important for thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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several regulators that inﬂuence the effect of degradation. Ubi-
quitin dependent system consists of 26 S multicatalytic protease
which includes two 19 S regulatory particles and 20 S core particle
in its structure [14]. Proteasome is responsible for the turnover of
several proteins of intracellular origin [15,16]. It has been shown
that the proteasomal system is responsible for the degradation of
oxidized proteins [17–19]. Since most of the therapeutic ap-
proaches for cancer therapy induce oxidative damage of proteins,
targeting proteasomal system is important to increase the efﬁ-
ciency of therapy. In addition, tumor cells have much higher
proteasome activity, most of which seems to be localized in the
nucleus when compared to nonmalignant cells. Thus, proteasomal
degradation contributes to the development of resistance. Re-
cently, the inhibition of the proteasome by speciﬁc inhibitors such
as bortezomib has been a novel target for cancer chemotherapy
since it has been shown to inhibit the growth of malignant tumor
cells [20,21].
In cellular defense mechanism which is developed against
oxidative damage, the transcription factor NF-E2-related factor 2
(Nrf2) controls transcriptional upregulation of antioxidant re-
sponse element (ARE)-bearing genes, including those encoding
endogenous antioxidants, phase II detoxifying enzymes and pro-
teasome subunits [22]. While Nrf2 pathway has been known to be
protective against cancer, recent work has revealed the “dark” side
of Nrf2. However, the antioxidant activity of Nrf2 contributes to
chemotherapy resistance by the induction of above mentioned
genes that are involved in cell survival and growth [23].
To improve the efﬁciency of heat therapy, the inhibition of re-
lated defense mechanisms may be accepted as a novel strategy for
cancer therapy. In our previous studies, we found that HSP70 and
HSP90 protein expressions increase [8] in response to heat treat-
ment in healthy young ﬁbroblast cells related to the changes in
proteasomal degradation. Our results lead us to hypothesize that
the inhibition of hyperthermia-induced proteolytic defense me-
chanisms by Nrf2 silencing may be a useful approach since Nrf2 is
known to regulate heat shock proteins and proteasome subunit
expressions. In the present study, we tested the protein levels of
HSP70, HSP40, HSP90, HO-1 and the proteasomal activity follow-
ing the combination of hyperthermia and siRNA knockdown of
Nrf2 in HT22 hippocampal tumor cell line. Our results revealed
that targeting Nrf2 pathway may be a useful approach to over-
come thermotolerance by the inhibition of defense mechanisms
and may bring future aspects for clinical use of thermotherapy.2. Material and methods
2.1. Cell culture and heat treatment
Mouse HT22 hippocampal cells were cultured in Dulbecco's
modiﬁed Eagle's medium supplemented with 100 U/ml penicillin,
100 μg/ml streptomycin, 10% fetal calf serum, and 0.35% glucose in
a humidiﬁed atmosphere of 5% CO2 and 95% air at 37 °C. Cells
initially were seeded at a density of 5105 cells/ml and then
grown for 3 days to a density of 3106 cells/ml for protein ex-
pression analysis. 1107 cells were grown to conﬂuence for nu-
clear extraction analysis. Conﬂuent cells were treated with mild
hyperthermia at 42 °C for 1 h in culture medium and used im-
mediately or used following culturing in a humidiﬁed atmosphere
of 5% CO2 and 95% air at 37 °C for 1 h prior to analysis.
2.2. Lysis and immunoblotting of HT22 cells
To obtain whole cell lysates for immunoblotting analysis, cells
were washed twice in 1 ml PBS and lysed with buffer containing10 mM Tris HCl (pH 7.5), 0,9% NP-40, 0,1% SDS, 1 mM Pefabloc, and
homogenized by passing through a 25-gauge needle ten times.
Insoluble material was removed by centrifugation at 14,000 rpm
for 20 min at 4 °C. The cytoplasmic and nuclear extracts were
performed through the instructions of Nuclear Extract Kit (Active
Motif, 40010). Protein concentrations were determined by BCA
method.
Following the heat treatment and lysis of HT22 cells, 30 μg of
whole cell lysates and nuclear lysates in reducing Laemmli-buffer
(0.25 M Tris pH 6.8, 8% SDS, 40% glycerol, 0.03% bromophenol
blue) were denatured at 95 °C for 5 min and applied to SDS-PAGE
of 12% (w/v) acrylamide, followed by electrophoresis and blotted
onto nitrocellulose membrane according to standard procedures.
Immunodetections were performed with the following antibodies:
anti-Nrf2 (D1Z9 C), anti-HSP90 (C45G5), anti-HSP70 (D69), anti-
HSP40, anti-HO-1 (P249), anti-proteasome β5, anti-GSTα and anti-
β-actin at 1:1000 dilutions. After exposure to peroxidase-coupled
secondary antibodies (Bio-Rad) at 1:5000 dilution, membranes
were developed using Lumi-Light western blotting substrate (Cell
Signaling). Blots were visualized using X-ray ﬁlm and quantiﬁed by
densitometry using Image J software.
2.3. Detection of mRNA levels by quantitative RT-PCR
Total RNA isolation was carried out by RNA Mini Kit (Qiagen).
The amount and purity of the RNA extracts were determined via
Smartspec spectrophotometry (Bio-Rad). cDNAwas synthesized by
iScript cDNA Synthesis kit (Biorad) using 100 ng total RNA.
Quantitative reverse transcriptase PCR was performed using Rotor
Gene Q-RT PCR system (Qiagen), and QuantiTect PCR Sybr Green
kit (Qiagen). PCR products were separated on 2.4% agarose gel in
order to control the product base pair and the bands were ex-
tracted using QIAquick gel extraction kit (Qiagen). The dsDNA
concentration of gel extractions were determined by spectro-
photometry and 101–1010 dilutions prepared to study standard
curve for quantitative analysis. The samples and the standard
curve were obtained simultaneously in one run, and the results
normalized to β-actin mRNA expression. The sequences of primers
used were:
mouse Nrf2 forward, 5′-CTCGCTGGAAAAAGAAGTGG-3′;
mouse Nrf2 reverse, 5′-CCGTCCAGGAGTTCAGAGAG-3′;
mouse β-actin forward, 5′-AGCCATGTACGTAGCCATCC-3′;
mouse β-actin reverse, 5′-CTCTCAGCTGTGGTGGTGAA-3′.
2.4. Nrf2 siRNA transfection
HT22 cells were transiently transfected with siRNA targeting to
Nrf2 by Accell siRNA delivery media (Dharmacon) according to the
manufacturer's protocol. Brieﬂy, 1.5105 cells were plated into a
12 well plate and incubated at 37 °C with 5% CO2 overnight. Re-
garding the number of the cells required for the nuclear extraction,
all of the siRNA experiments were performed only in whole cells
lysates and nuclear extraction was not performed with siRNA cells.
1 mM ﬁnal concentration of Nrf2 siRNA (Smartpool, Dharmacon) in
1 siRNA buffer diluted from 5 siRNA buffer (Dharmacon) was
added to the wells. The cells were incubated at 37 °C with 5% CO2
for 72 h. The knockdown efﬁciency of Nrf2 was determined by QRT
PCR analysis and 70% inhibition of Nrf2 mRNA level was detected.
After 72 h of transfection, the cells were treated by hyperthermia
at 42 °C for 1 h in delivery media and used immediately or fol-
lowing culturing in a humidiﬁed atmosphere of 5% CO2 and 95% air
at 37 °C for 1 h prior to analysis. Then, the cells were lysed for
immunoblotting analysis.
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The proteasome activity was measured in whole cell extracts,
cytoplasmic and nuclear lysates of HT22 cells that are treated with
hyperthermia. Peptidase activity toward the ﬂuorogenic peptide
substrate succinyl–leucine–leucine–valine–tyrosine–methylcou-
maryl amide (suc-LLVY-MCA) was determined by incubation of
samples with reaction buffer (150 mM Tris, 30 mM KCl, 5 mM
MgOAc, 5 mM MgCl2, 0.5 mM DTT, and 200 μM suc-LLVY-MCA) for
45 min at 37 °C. Fluorescence of the liberated methylcoumarin
(MCA) was monitored using a micro plate reader at 360 nm ex-
citation and 460 nm emission wavelengths. The amount of sub-
strate degradation was calculated using the calibration curve
prepared with free MCA standards as nmol MCA/mg proteinxmin.
2.6. Protein carbonyl measurement by Oxyblot
Following heat treatment, HT22 cells were lysed as explained
above, 20 μg of total proteins were reduced by Laemmli-buffer and
denatured at 95 °C for 5 min and applied to SDS-PAGE of 10% (w/v)
acrylamide and followed by electrophoresis. The proteins for
blotting were transferred onto a nitrocellulose membrane by
Turbo Trans-blot system (Bio-Rad Laboratories). Following the
electroblotting step, the membranes were equilibrated in TBS
(100 mM Tris, 150 mM NaCl, pH 7.5) containing 20% methanol for
5 min, washed in 2N HCl for 5 min, incubated with 10 mM DNPH
solution for 5 min, washed 35 min in 2N HCl and washed
55 min in 50% methanol. DNPH treated membrane was blocked
with 5% non-fat dry milk in TBST (TBS contains Tween 20) for 1 h
at room temperature with constant agitation. Blocked membrane
was washed 35 min with TBST and incubated with rabbit anti-
DNP antibody (Sigma) freshly diluted 1:2500 in 5% non-fat dryA
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1 h as described in Materials and Methods. The groups of HT22 cells are represented as
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Blotted membrane was washed 35 min with TBST and incubated
with secondary anti-rabbit antibody (Bio-Rad) freshly diluted
1:5000 in 5% non-fat dry milk/TBST for 1 h at room temperature
with constant agitation. The blotted membrane was washed
55 min with TBST. Membrane was developed using Lumi-Light
western blotting substrate.
2.7. Statistical analyses
Statistical analysis was performed using Prism 4 (Graph-Pad)
software. For determination of statistical signiﬁcances of differ-
ences, one-way ANOVA was performed followed by multiple com-
parisons using the Student–Newman–Keuls test multiple compar-
ison test. Po0.05 was considered as statistically signiﬁcant.3. Results
3.1. Heat treatment increases nuclear protein expressions of Nrf2 in
HT22 cells
The effects of hyperthermia at 42 °C for 1 h (without and with
recovery at 37 °C for 1 h) on the protein expressions of Nrf2 in
whole cell lysates and nuclear extracts were analyzed by im-
munoblotting (Fig. 1). Nrf2 protein expression was signiﬁcantly
increased by heat treatment that was reduced by recovery
(Fig. 1A). This increase was more prominent in the nuclear protein
expressions of Nrf2 following hyperthermia (Fig. 1B). To be able to
conﬁrm the purity of cytoplasmic and nuclear extracts, we per-
formed immunoblotting of GAPDH and PARP (Fig. 1C). Interest-
ingly, protein expressions of Nrf2 in the cytoplasmic extracts were0
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cells.
3.2. HO-1 and GSTα expressions increase following heat treatment
As target genes of Nrf2, HO-1 and GSTα protein expressions
were analyzed following heat treatment. Both HO-1 and GSTα
expressions were signiﬁcantly induced by hyperthermia (Figs. 2A–
B). These results demonstrated that the activation of antioxidant
enzymes HO-1 and GSTα via Nrf2 pathway might play a role in
cellular defense during heat treatment.
3.3. Heat treatment increases protein carbonylation in HT22 cells
Protein carbonyls are the most widely measured biomarkers for
protein oxidation because of the relatively early formation and the
stability of carbonylated proteins. The amount of protein bound
carbonyls were measured following the heat treatment of HT22
cells according to Buss et al. [24]. The protein carbonyl content of
cells was signiﬁcantly enhanced with heat treatment that wasβ-actin
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Fig. 3. Heat treatment increases protein carbonyl formation in HT22 cells. Cells were ly
DNPH-reaction using a rabbit polyclonal anti-DNP (dinitrophenyl) primary antibody. The
recovery, C: 1 h of hyperthermia with recovery at 37 °C. Data are represented as mean7
lysates. (B) Densitometric analysis of protein carbonyl expression relative to β-actin. *Poreduced by 1 h recovery (Fig. 3A). Increase of the oxidative damage
in the cell may be related to the upregulation of Nrf2 expression
and proteasomal activity as defense mechanisms.3.4. Hyperthermia induces both proteasome activity and the protein
expression of proteasome subunit β5 in the nucleus
To test the role of hyperthermia in HT22 cells, proteasomal
activity was measured by ﬂuorometric detection method and we
observed a signiﬁcant increase in proteasomal activity of whole
cells lysates which was decreased by 1 h recovery (Fig. 4A).
However, the analysis of proteasomal activity in cytoplasmic and
nuclear extracts showed that proteasome was activated in the
nucleus and the activity was even decreased in the cytoplasm by
hyperthermia (Fig. 4B–C). Consistent with our ﬁnding that Nrf2
expressions and proteasomal activity were increased in the nu-
cleus of hyperthermia treated group, protein expression of pro-
teasome subunit β5 was also signiﬁcantly elevated in the nucleus
when compared to control group (Fig. 4E).PC
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cells
In order to gain information whether HSPs are affected by hy-
perthermia in HT22 cells, HSP70, HSP40 and HSP90 protein ex-
pressions were analyzed by immunoblotting (Fig. 5). HSP70 pro-
tein expressions were determined in cytoplasmic and nuclear ex-
tracts since HSP70 is known to translocate to the nucleus to in-
teract with misfolded proteins [25]. Hyperthermia decreased the
expression of HSP70 in cytoplasmic extracts (Fig. 5A) while it was
signiﬁcantly increased in nuclear extracts by both heat treatment
and recovery when compared to controls (Fig. 5B). HSP40 ex-
pression was decreased by hyperthermia in correlation with re-
duced cytoplasmic HSP70 expression, was also signiﬁcantly de-
creased in recovery group when compared to controls (Fig. 5C).
These results are correlated with increased proteasomal activity
that can be explained by the fact that HSP40 and HSP70 bind to
the proteasome to target their substrates for the degradation. On
the other hand, HSP90 protein expression was signiﬁcantly in-
creased by heat treatment in HT22 cells (Fig. 5D).
3.6. Nrf2 silencing decreases antioxidant defense by reduced HO-1
expression
In the present study, we showed that thermotholerance was
gained against hyperthermia treatment either by antioxidant en-
zymes and proteolytic defense. Regarding our results, we aimed toinhibit thermotholerance by Nrf2 silencing. We treated cells with
Nrf2 siRNA that are exposed to hyperthermia. Nrf2 silencing was
checked by qRT-PCR analysis and we observed 70% reduction in
Nrf2 mRNA expression when compared to control group (Fig. 6A).
Consequently, 9-fold induction of HO-1 protein expression by
hyperthermia (Fig. 2A) was reduced to 1.5 fold following Nrf2
siRNA transfection (Fig. 6B), conﬁrming the role of Nrf2 in heat
induced HO-1 expression.
3.7. Nrf2 silencing inhibits proteasome induction of heat treatment
When the cells were transfected with Nrf2 siRNA, the in-
crease of proteasomal activity that is stimulated by heat treat-
ment (Fig. 4A) was inhibited and there was no change between
the groups (Fig. 7A). Moreover, in the same direction with the
proteasomal activity results, Nrf2 silencing resulted in no sig-
niﬁcant change of proteasome subunit β5 expression between
the groups (Fig. 7B) and induction of the nuclear β5 expression
may be inhibited by Nrf2 siRNA transfection (Fig. 4E). In addi-
tion, we aimed to correlate the role of Nrf2 in HSP induced
proteasomal degradation. In this direction, HSP40 and HSP90
protein expressions were determined in addition to HSP70
protein expression. Following Nrf2 siRNA treatment, there was
no signiﬁcant change of HSP70 protein expression between the
groups (Fig. 8A). Following Nrf2 silencing, signiﬁcant increase of
HSP40 expression by heat treatment (Fig. 8B) may be resulted
from its liberation from inhibited proteasome [26]. Nrf2
050
100
150
A B C
A B
H
SP
70
 / 
G
A
PD
H
H
SP
70
 / 
PA
R
P
0
100
200
300
400
500
600
700
800
A B C
*
*
# &
Cytoplasmic HSP70
GAPDH
Nuclear HSP70
PARP
Cytoplasmic HSP70 protein expression in HT22 cells Nuclear HSP70 protein expression in HT22 cells
0
50
100
150
A B C
HSP40 protein expression in HT22 cells
H
SP
40
 / 
β-
ac
tin
*
#
C
HSP40
β-actin
D
0
50
100
150
200
A B C
HSP90 protein expression in HT22 cells
H
SP
90
 / 
β-
ac
tin *
HSP90
β-actin
Fig. 5. Heat stress affects HSP expressions differently in HT22 cells. HSP70 protein expression was determined by immunoblotting in cytoplasmic and nuclear lysates. HSP40
and HSP90 protein expressions were determined by immunoblotting in whole cell extracts. The groups of HT22 cells are represented as A: Control, B: 1 h of hyperthermia
without recovery, C: 1 h of hyperthermia with recovery at 37 °C for 1 h for Fig. 5A, B, C and D. Data are represented as mean7S.D., (n¼3). (A) Representative immunoblots
for HSP70 and GAPDH expressions and densitometric analysis of HSP70 protein expression in cytoplasmic extracts relative to GAPDH.*Po0.05 for B vs. A. (B) Representative
immunoblots for HSP70 and PARP expressions and densitometric analysis of HSP70 nuclear protein expression relative to PARP. *Po0.05 for B vs. A, #Po0.05 for C vs. A,
&Po0.05 for C vs. B. (C) Representative immunoblots for HSP40 and β-actin expressions and densitometric analysis of HSP40 protein expression relative to β-actin in whole
cell extracts.*Po0.05 for B vs. A, #Po0.05 for C vs. A. (D) Representative immunoblots for HSP90 and β-actin expressions and densitometric analysis of HSP90 protein
expression in whole cell lysates relative to β-actin.*Po0.05 for B vs. A.
P. Bozaykut et al. / Redox Biology 8 (2016) 323–332328silencing was found to result in no signiﬁcant effect on HSP90
protein expression (Fig. 6C).4. Discussion
NF-E2-related factor 2 (Nrf2) signaling pathway is a main cel-
lular detoxiﬁcation program, has been regarded as beneﬁcial for its
antioxidant capacity for normal cells. However, recent work has
undercut the notion that antioxidant activity is unambiguously
protective against cancer progress [27]. In basal conditions, Nrf2 is
inactivated in the cytoplasm by Kelch-like ECH-associated protein
1 (Keap1) which targets Nrf2 for ubiquitination and degradation
by the proteasome [28]. Under stress conditions including oxida-
tive, electrophilic or heat stress, Nrf2 is liberated from Keap1
which in turn translocates into the nucleus where it stimulates the
expression of phase II and antioxidant enzymes including NAD(P)
H quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HO-1),
glutamanecysteine ligase (GCL) and glutathione S transferases
(GSTs) [29–31]. Previously, our group showed that HSP70 proteinlevels were elevated in response to heat stress followed by re-
covery in young ﬁbroblast cells [8]. This increase in HSP70 was
related to, increased proteasomal activity. Thus, in the present
study, we targeted Nrf2 silencing to evaluate possible contribution
of Nrf2 in the development of proteasomal degradation response
developed against hyperthermia in HT22 hippocampal tumor cell
line.
Protein carbonyls are the most widely measured biomarkers of
protein oxidation, as they are, in general, stable products formed
relatively early during oxidative stress [18,32]. Protein carbonyl
formation is also a good indicator of protein damage following
cancer therapy [17,33]. Following heat treatment, protein carbo-
nylation of the cells was measured by oxyblot as a biomarker of
oxidative protein damage. We found a signiﬁcant increase of
protein carbonylation that was decreased after recovery of one
hour in HT22 cells. Regarding the increase of oxidative stress,
which is mediated by hyperthermia, we tested Nrf2 protein ex-
pression and its translocation to the nucleus. Nrf2 protein ex-
pression was found to be signiﬁcantly elevated by heat treatment,
which contributes, to the protection of cell via antioxidant
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P. Bozaykut et al. / Redox Biology 8 (2016) 323–332 329mechanisms. Interestingly, the increase of Nrf2 expression was
originating from the nucleus and both in normal and heat stressed
conditions, there was almost no Nrf2 protein in the cytoplasm.
This showed that Nrf2 was already active in the nucleus of HT22
cells. The upregulation of antioxidant system in hyperthermia
conditions was proved by elevated HO-1 and GSTα protein ex-
pressions, demonstrates that nuclear Nrf2 expression leads to the
antioxidant cellular defense. Our data suggested the requirement
of Nrf2 silencing and this may be a useful approach in aspect of
suppressing the protection gained by antioxidant systems. In this
direction, the decrease in the heat-induced HO-1 expression fol-
lowing siRNA transfection conﬁrms the involvement of Nrf2
pathway via antioxidant mechanism in thermotolerance.
Moreover, Nrf2 may also be responsible for chemoresistance in
terms of cellular proteostasis since Nrf2 regulates the expression
of molecular chaperones [34], as well as of additional players of0
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cer cells following hyperthermia enhances tumor cell viability and
impart increase resistance to subsequent chemotherapy [37]. The
protection of cells against protein-damaging agents is provided by
the increased HSPs both by affecting protein chaperoning and
refolding and by directly blocking the cell-death pathways [38–
40]. Additionally, the upregulation of HSPs frequently compro-
mises the effects of thermotherapy [41,42]. Targeting HSP inhibi-
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related proteasome activation directly from the transcriptional
process via Nrf2 pathway. In our study, we observed increased
HSP90 expression following heat treatment. Interestingly, HSP70
protein expression was increased in nuclear extracts by heat
treatment showed that in correlation with Nrf2, HSP70 was also
active in the nucleus. The decrease in cytoplasmic HSP70 expres-
sion may be due to the translocation of HSP70 to the nucleus and
HSP70 translocation was also conﬁrmed in other studies for the
protection of DNA against several conditions [25,43]. Together
with the decrease of HSP70 in the cytoplasm, HSP40 levels were
also decreased in the cells. These results are consistent with pre-
vious studies, which showed that HSP expressions may be induced
or repressed in different cell lines [44] and repression is generally
accompanied by the translocation into the nucleus [45]. In the
present study, thermotolerance gained by elevated HSP70 ex-
pression and related proteasome activation was inhibited follow-
ing Nrf2 siRNA treatment. Nrf2 silencing resulted in a decrease of
hyperthermia-induced HSP70 expression and there was no sig-
niﬁcant change between the groups. Meanwhile, Nrf2 silencing
did not affect HSP90 expression signiﬁcantly. Decreased HSP40expression by hyperthermia was found to be induced following
Nrf2 siRNA treatment, which may be explained by the inhibition of
proteasomal degradation.
In mammalian cells, a range of proteases exists which are dis-
tributed throughout the cell and the major proteolytic system
responsible for the removal of oxidized proteins is the proteasomal
system [46]. 26 S proteasome is a multicomponent proteinase re-
sponsible for the turnover of the majority of proteins of in-
tracellular origin [15,16] and it can control the expression of many
relatively short-lived regulatory proteins involved in cell growth
and proliferation. Originally thought of as an indiscriminate pro-
tein digestive system, it is now recognized as a highly coordinated
regulatory pathway that is present in the nucleus and in the cy-
toplasm [47]. Recently, the discovery that speciﬁc inhibitors of the
ubiquitin proteasome pathway inhibit the growth of malignant
tumor cells has led to a growing interest in the proteasome as a
novel target for cancer chemotherapy [20]. On the other hand,
proteasome inhibition was shown to induce the elevation of Nrf2
and HO-1 in a HDAC6 coordinated mechanism that could impair
the efﬁciency of proteasome inhibitor treatment [48–50]. In the
current study, we both analyzed the proteasomal activity and
P. Bozaykut et al. / Redox Biology 8 (2016) 323–332 331proteasome β5 expression following heat treatment and Nrf2
siRNA transfection. Proteasomal activity was signiﬁcantly in-
creased in the whole cell lysates by hyperthermia and was de-
creased by 1 h recovery. However, the analysis of proteasomal
activity in cytoplasmic and nuclear extracts showed that protea-
some was activated in the nucleus and the activity was decreased
in the cytoplasm by hyperthermia. This may be explained together
with the translocation of HSP70 to the nucleus and also the role of
HSP70 for the association of 26 S proteasome for the activation
[26]. When the cells were transfected with Nrf2 siRNA, the in-
crease of proteasomal activity that was stimulated by heat treat-
ment was inhibited. Similarly, nuclear expression of proteasome
subunit β5 was also elevated by heat treatment and Nrf2 silencing
reduced the signiﬁcant increase of β5 expression. Depending on
our results, in the same direction with Nrf2 expression, both
proteasomal activity and proteasome expression were found to be
more active in the nucleus and it seems proteasome translocates
to the nucleus in heat stress conditions. Consequently, their acti-
vation by heat stress was inhibited in whole cell lysates by Nrf2
silencing. These results supported our previous data that oxidative
damage in HT22 tumor cells that was supposed to be also a con-
sequence of chemotherapy was ameliorated by nuclear protea-
some [17] which was inhibited by Nrf2 pathway in our study.
The results from various studies have shown that hyperthermia
is both ideal complementary treatment to, and a strong sensitizer
of, both chemo- and radiotherapy [51,52]. Additionally, the ex-
pectations raised by the experimental studies have been con-
ﬁrmed by the results from clinical studies [53–55]. In spite of the
remarkable therapeutic gain that has now been demonstrated in
patients, hyperthermia is still not widely recognized as a useful
treatment due to the development of thermotolerance. In this
point, Nrf2 may contribute to improve the effectiveness of hy-
perthermia by the inhibition of defense mechanisms that are in-
duced during the therapy in several ways. In the present study,
Nrf2 silencing inhibited both proteasome activity and expression
which contributes to acquisition of thermotolerance. Regarding
our results, an inhibitor of Nrf2 can be used in conjunction with
thermotherapy to sensitize cancer cells to chemical treatment.
Since Nrf2 is proved to regulate the expression of several down-
stream genes related to antioxidant systems and cellular pro-
teostasis protecting cancer cells, it would be a more efﬁcient drug
target than the individual downstream gene.5. Conclusion
In conclusion, we showed that targeting Nrf2 might be a useful
approach for the acquisition of thermotolerance through inhibi-
tion of various defense mechanisms. Our results demonstrated
that these mechanisms that are affected by Nrf2 activation are the
antioxidant players such as HO-1 and GSTα and players of protein
turnover including HSPs and the proteasomal system. In addition,
we showed that all of these factors are mostly active in the nucleus
of the cell. Therefore, in order to inhibit development of thermo-
tolerance gained by proteasome and antioxidant systems, repres-
sion of Nrf2 signaling pathway would contribute to the efﬁciency
of hyperthermic therapy in human cancers.Acknowledgment
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